Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments regarding the government response to the COVID-19 pandemic.

Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...